Arthrokatadysis from post-injection gluteal muscular fibrosis case report.

BMC Musculoskelet Disord

Department of Orthopedics, School of Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, NO.301 Yanchang Middle Road, Shanghai, 200072, China.

Published: November 2020

Background: Gluteal muscle contracture (GMC) is a clinical syndrome characterized by the contracture of gluteal muscles, iliotibial band (ITB), and related fascia. GMC is much more prevalent in China, which has been proven to be associated with repeated intramuscular injections into the buttocks and the subsequent fibrosis and contracture.Generally, GMC is manifested mild. Here, we reported a severe case with arthrokatadysis.

Case Presentations: A 25-year old man received multiple intramuscular injections of penicillin in the buttock when he was diagnosed with acute tonsillitis at 6 years old. Since then, he was injected penicillin regularly in local hospital because of the repeated acute tonsillitis until he was in high school. When the patient was found by the physical education teacher to be running in a state of external rotation of both feet, he was suggested to go to the hospital for treatment and was initially diagnosed to have GMC. He complained of occasional pain and limited range of motion in the hip joints. X-ray showed a typical arthrokatadysis. After arthroscopic release of GMC, the patient recovered well.

Conclusions: This is possibly the first reported case of arthrokatadysis that was caused by GMC after repeated intramuscular injections into the buttocks. Although the patient recovered well by arthroscopic surgical release of bilateral gluteus maximus contractures, GMC should be paid more attention and treated as early as possible.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666455PMC
http://dx.doi.org/10.1186/s12891-020-03766-5DOI Listing

Publication Analysis

Top Keywords

intramuscular injections
12
repeated intramuscular
8
injections buttocks
8
patient recovered
8
gmc
7
arthrokatadysis post-injection
4
post-injection gluteal
4
gluteal muscular
4
muscular fibrosis
4
fibrosis case
4

Similar Publications

An 86-year-old male patient developed paresthesia in both hands, and six months later, pancytopenia was noted. He was diagnosed with myelodysplastic syndrome following bone marrow aspiration. Despite high serum vitamin B12 level, elevated level of serum homocysteine, positive anti-intrinsic factor antibody, and T-weighted hyperintense lesions on spinal cord MRI led to a diagnosis of subacute combined degeneration of the spinal cord.

View Article and Find Full Text PDF
Article Synopsis
  • CAB + RPV is the first long-acting HIV treatment regimen using thigh injections, showing promising results in maintaining viral suppression.
  • The study involved 118 participants and compared pharmacokinetic changes and tolerability between thigh and gluteal injections, finding no significant differences in effectiveness.
  • Results indicated that a majority of participants preferred thigh injections, with potential plans for more flexible dosing schedules to enhance treatment convenience.
View Article and Find Full Text PDF

Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a long-acting injectable antipsychotic that was approved for use in Europe in March 2024, for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole; it is administered via gluteal intramuscular injection once every two months. This review examines population pharmacokinetic model-based simulations relevant to the use of Ari 2MRTU in Europe, accompanied by expert commentary that contextualizes the simulations and highlights the potential implications of the availability of Ari 2MRTU for patients, caregivers, and clinicians. Various simulations conducted across 8 weeks (representing the first dosing interval), or 32 weeks (representing maintenance dosing) demonstrated an aripiprazole exposure profile for Ari 2MRTU that was similar to aripiprazole once-monthly (AOM), but with an extended dosing interval.

View Article and Find Full Text PDF

Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites.

Mol Ther Methods Clin Dev

March 2025

Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA.

Lipid nanoparticles (LNPs) are often liver tropic, presenting challenges for LNP-delivered mRNA therapeutics intended for other tissues, as off-target expression in the liver may increase side effects and modulate immune responses. To avoid off-target expression in the liver, miR-122 binding sites have been used by others in viral and non-viral therapeutics. Here, we use a luciferase reporter system to compare different copy numbers and insertion locations of miR-122 binding sequences to restrict liver expression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!